Trade Report: Today: Perkins Capital Management Inc. Raises its position in Entellus Medical Inc. (ENTL) as a favorable investment target.

Today: Perkins Capital Management Inc. Raises its position in Entellus Medical Inc. (ENTL) as a favorable investment target.

Perkins Capital Management Inc. boosted its position in shares of Entellus Medical Inc. (NASDAQ:ENTL) by 119.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,450 shares of the medical technology company’s stock after buying an additional 26,950 shares during the period. Perkins Capital Management Inc. owned approximately 0.26% of Entellus Medical worth $1,097,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Murphy Michael R raised its position in shares of Entellus Medical by 30.1% in the second quarter. Murphy Michael R now owns 627,441 shares of the medical technology company’s stock worth $11,463,000 after buying an additional 145,304 shares in the last quarter. Cortina Asset Management LLC raised its position in shares of Entellus Medical by 39.2% in the second quarter. Cortina Asset Management LLC now owns 421,897 shares of the medical technology company’s stock worth $7,708,000 after buying an additional 118,745 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Entellus Medical by 5.1% in the second quarter. Vanguard Group Inc. now owns 215,395 shares of the medical technology company’s stock worth $3,936,000 after buying an additional 10,532 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Entellus Medical by 40.1% in the second quarter. BlackRock Fund Advisors now owns 195,518 shares of the medical technology company’s stock worth $3,572,000 after buying an additional 55,996 shares in the last quarter. Finally, Ghost Tree Capital LLC raised its position in shares of Entellus Medical by 9.1% in the second quarter. Ghost Tree Capital LLC now owns 120,000 shares of the medical technology company’s stock worth $2,192,000 after buying an additional 10,000 shares in the last quarter. 71.55% of the stock is currently owned by institutional investors and hedge funds.

Shares of Entellus Medical Inc. (NASDAQ:ENTL) traded up 0.05% during trading on Monday, reaching $19.18. The company’s stock had a trading volume of 7,717 shares. The firm’s market capitalization is $361.81 million. Entellus Medical Inc. has a 52 week low of $13.72 and a 52 week high of $22.63. The company has a 50 day moving average price of $19.12 and a 200 day moving average price of $18.64.

Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings results on Thursday, November 3rd. The medical technology company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.13. The business had revenue of $17.90 million for the quarter, compared to analysts’ expectations of $17.93 million. Entellus Medical had a negative return on equity of 53.20% and a negative net margin of 36.91%. The firm’s quarterly revenue was up 20.9% on a year-over-year basis. During the same period last year, the firm earned ($0.32) earnings per share. On average, equities research analysts expect that Entellus Medical Inc. will post ($1.42) EPS for the current fiscal year.

A number of analysts have recently commented on ENTL shares. Zacks Investment Research downgraded Entellus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, November 8th. Deutsche Bank AG restated a “buy” rating and issued a $26.00 target price (up previously from $25.00) on shares of Entellus Medical in a research note on Friday, November 4th. BTIG Research restated a “buy” rating and issued a $22.00 target price on shares of Entellus Medical in a research note on Friday, August 5th. Finally, Canaccord Genuity restated a “buy” rating and issued a $23.00 target price on shares of Entellus Medical in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $22.75.

In other Entellus Medical news, Director Brian E. Farley sold 17,006 shares of Entellus Medical stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $19.33, for a total transaction of $328,725.98. Following the completion of the sale, the director now directly owns 560,265 shares of the company’s stock, valued at approximately $10,829,922.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian E. Farley sold 10,000 shares of Entellus Medical stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $18.30, for a total value of $183,000.00. Following the sale, the director now directly owns 509,581 shares of the company’s stock, valued at $9,325,332.30. The disclosure for this sale can be found here. Company insiders own 9.10% of the company’s stock.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

Related posts

Leave a Comment